Phase 3 RCT in 263 adults with t(11;14) relapsed/refractory multiple myeloma: venetoclax-dexamethasone did not significantly improve PFS vs pomalidomide-dexamethasone (median 9.9 vs 5.8 months; HR 0.823, P=.24); treatment-emergent deaths 12% vs 6%.
RCTn = 263
Popat et al. Venetoclax-Dexamethasone Versus Pomalidomide-Dexamethasone in t(11;14)-Positive Relapsed/Refractory Multiple Myeloma: Primary Results of the Randomized, Phase III CANOVA Study